POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy
Recruiting
Phase 2
Interventional Study
Acute Coronary Syndrome
CYP2C19 Polymorphism
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 200 (estimated)
- Sponsor
- St. Antonius Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this pilot clinical trial is to test the safety and effectiveness of genotype-guided clopidogrel monotherapy in patients presenting with Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) who have undergone successful Percutaneous Coronary Intervention (PCI). The main questions it aims to answer are:
* Is genotype-guided clopidogrel monotherapy effective in reducing ischemic …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Patients aged 18 years or older are eligible for inclusion if all of the following criteria are met:
* Clinical diagnosis of NSTE-ACS (i.e. NSTEMI or unstable angina)
* Successful PCI (according to the treating physician) with implantation of new generation drug eluting stents.…
Contacts